Klinická farmakologie a farmacie – 2/2020

www.klinickafarmakologie.cz  / Klin Farmakol Farm 2020; 34(2): 78–83 / KLINICKÁ FARMAKOLOGIE A FARMACIE 83 PŘEHLEDOVÉ ČLÁNKY Aktuality vo farmakoterapii astmy bronchiale LITERATÚRA 1. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2019. Dostupné na: www.gi­ nasthma.org 2. The European Lung White Book. Respiratory health and disease in Europe. ISBN 978–1–84984–042–2 3. Národné centrum zdravotníckych informácií. Zdravotnícka ročenka Slovenskej republiky 2018. ISBN 978–80–89292–71–4 4. Meilinger M, Horváth I, Laššán Š, et al. Asthma control and perception from patient perspective in the Central Europe­ an region. The ASCERTAIN survey. Pneumo Update Europe Poster. 9–10 June 2017, Vienna. 5. O’Byrne P, Fabbri LM, Pavord ID, et al. Asthma progression and mortality: the role of inhaled corticosteroids. Eur Respir J 2019; 54: 1900491. 6. Kuruvilla ME, Lee FEH, Lee GB. Understanding asthma phe­ notypes, endotypes and mechanisms of disease. Clin rev Allergy Immunol 2019; 56(2): 219–233. 7. OzdemirC,KucuksezerUC,AkdisM,etal.Theconceptsofast­ hmaendotypesandphenotypestoguidecurentandnoveltre­ atment strategies. Expert Rev Respir Med 2018; 12(9): 733–743. 8. Papi A, Brightling C, Pedersen SE, et al. Asthma. Lancet 2018; 391: 783–800. 9. Holguin F, Cardet JC, Chung KF, et al. Management of seve­ re asthma: a European Respiraory Society/American Thoracic Society guideline. Eur Respir J 2020; 55: 1900588. 10. Laššán Š, Téglás I, Laššánová M. Targeting asthma control in real‑life clinical practice by using ICS/LABA combination. Klin Farmakol Farm 2018; 33(3): 21–27. 11. Muneswarao J, Hassali MA, Ibrahim B, et al. I tis time to change the way we manage mild asthma: an update in GINA 2019. Respir Res 2019; 20: 183. 12. Barnes PJ, Szelfer SJ, Reddel HK, et al. Symptoms and per­ ception of airway obstruction in asthmatic patients: Clinical implications for use of reliever medications. J Allergy Clin Im­ munol 2019; 144: 1180–1186. 13. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2018. Dostupné na: www.gi­ nasthma.org 14. Global Initiative for Asthma. Diificult‑to‑treat & Severe As­ thma in adolescent and adult aptients. Diagnosis and man­ agement. V2.0 April 2019. Dostupné na: www.ginasthma.org 15. Papi A, Canonica GW, Maestrelli P, et al. Rescue use of beclomethasone and albuterol in a single inhaler for mild asthma. N Engl J Med 2007; 356: 2040–2052. 16. Calhoun WJ, Ameredes BT, King TS, et al. Comparison of Physician-, Biomarker-, and Symptom- Based Strategies for Adjustment of Inhaled Corticosteroid Therapy in Adul­ ts with Asthma. The BASALT Randomized Controlled Trial. JAMA 2012; 308(10): 987–997. 17. Martinez FD, Chinchilli VM, Morgan WJ, et al. Use of bec­ lomethasone dipropionate as rescue treatment for children with mild persistent asthma (TREXA): a randomised, double­ ‑blind, placebo‑controlled trial. Lancet 2011; 377: 650–657. 18. O’Byrne PM, FitzGerald M, Bateman ED, et al. Inhaled Budesonide‑Formoterol as Needed in Mild Asthma. N Engl J Mešd 2018; 378: 1865–1876. 19. Bateman ED, Reddel HK, O’Byrne PM, et al. Inhaled Budesonide‑Formoterol versus Maintenance Budesonide in Mild Asthma. N Engl J Med 2018; 378: 1877–1887. 20. Beasley R, Holliday M, Reddel HK, et al. Controlled Trial of Budesonide‑Formoterol as Needed for Mild Asthma. N Engl J Med 2019; 380: 2020–2030. 21. Hinds D, Gibbons DC, Gunsoy NB, et al. Eligibility for newer biologic therapies in severe asthma, re‑analysis of the IDEAL study. Poster No. 1008 (A5926). ATS International Conceren­ ce, Dallas, May 17–22, 2019. 22. Chapman KR, Albers FC, Chipps B, et al. The clinical benefit of mepolizumab replacing omalizumab in uncontrolled se­ vere eosinophilic asthma. Allergy 2019; DOI: 10.1111/all.13850.